Market Size of Hepatorenal Syndrome Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hepatorenal Syndrome Treatment Market Analysis
The hepatorenal syndrome treatment market is projected to record a CAGR of nearly 6.2% over the forecast period. Hepatorenal syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. As the kidneys stop functioning, toxins begin to build up in the body. Eventually, this leads to liver failure. The major factor attributing to the growth of the market is the increase in the prevalence of liver damage and cirrhosis. According to the Centers for Disease Control and Prevention, 4.5 million adults are diagnosed with chronic liver disease in the year 2018, in the United States alone. Furthermore, increasing fast-track and orphan drug designations boosts the market growth. However, side effects with the drugs and stringent regulations are restraining the market growth.
Hepatorenal Syndrome Treatment Industry Segmentation
Hepatorenal syndrome is the development of renal failure in patients with advanced chronic liver disease. This report is segmented by treatment, and by geography.
| By Treatment | |
| Therapeutics | |
| Liver Transplantation | |
| Surgical Shunting | |
| Renal Replacement Therapy | |
| Other Treatments |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hepatorenal Syndrome Treatment Market Size Summary
The hepatorenal syndrome treatment market is anticipated to experience steady growth over the forecast period, driven by the increasing prevalence of liver damage and cirrhosis. This condition, characterized by progressive kidney failure due to severe liver damage, often leads to liver failure as toxins accumulate in the body. The market's expansion is further supported by the growing number of fast-track and orphan drug designations, which expedite the approval process for therapeutics. Despite these positive trends, the market faces challenges such as drug side effects and stringent regulatory requirements. The therapeutics segment is expected to see significant growth, as patients tend to prefer drug treatments over surgical options, with several drugs receiving orphan designations that enhance their market potential.
North America is projected to lead the hepatorenal syndrome treatment market, attributed to its robust healthcare infrastructure, the presence of key industry players, and a high prevalence of severe liver conditions. The United States, in particular, holds a significant market share due to supportive healthcare policies and a developed healthcare system. The market's competitive landscape is moderately intense, with major companies like Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, and others playing pivotal roles. These companies, along with beneficial government initiatives and increased research collaborations, are expected to drive market growth in the region.
Hepatorenal Syndrome Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Severe Liver Damage Which Often Leads to Hepatorenal Syndrome
-
1.2.2 Increasing Fast Track and Orphan Drug Designations
-
-
1.3 Market Restraints
-
1.3.1 Side-effects and Risks Related to Drug Usage
-
1.3.2 Stringent Regulatory Requirements
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Treatment
-
2.1.1 Therapeutics
-
2.1.2 Liver Transplantation
-
2.1.3 Surgical Shunting
-
2.1.4 Renal Replacement Therapy
-
2.1.5 Other Treatments
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle-East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle-East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Hepatorenal Syndrome Treatment Market Size FAQs
What is the current Hepatorenal Syndrome Treatment Market size?
The Hepatorenal Syndrome Treatment Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Hepatorenal Syndrome Treatment Market?
Cumberland Pharmaceuticals Inc. , Mallinckrodt Pharmaceuticals, New Medicon Pharma Lab, Becton, Dickinson and Company and Edwards Lifesciences Corporation are the major companies operating in the Hepatorenal Syndrome Treatment Market.
